176 related articles for article (PubMed ID: 31541747)
1. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
2. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
3. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
4. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
Pariser DM; Bagel J; Lebwohl M; Yosipovitch G; Chien E; Spellman MC
J Am Acad Dermatol; 2020 Jun; 82(6):1314-1320. PubMed ID: 32007513
[TBL] [Abstract][Full Text] [Related]
5. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
6. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
7. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
8. Benefits and harms of NK
Yang Y; Guo L; Chen Z; Jiang X; Liu Y
Dermatol Ther; 2021 Jan; 34(1):e14698. PubMed ID: 33368902
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
[TBL] [Abstract][Full Text] [Related]
10. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
[TBL] [Abstract][Full Text] [Related]
11. Topical gabapentin 10% in the treatment of epidermolysis bullosa pruritus: A pilot, double-blind, split-site, randomized controlled trial.
Saki N; Vahedi S; Parvizi MM; Shafie'ei M; Hosseini SA; Ahramiyanpour N
Dermatol Ther; 2022 Oct; 35(10):e15767. PubMed ID: 36117146
[TBL] [Abstract][Full Text] [Related]
12. Burden of itch in epidermolysis bullosa.
Snauwaert JJ; Yuen WY; Jonkman MF; Moons P; Naulaers G; Morren MA
Br J Dermatol; 2014 Jul; 171(1):73-8. PubMed ID: 24506095
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series.
Kwon IJ; Kim SE; Kim SC; Lee SE
J Dermatol; 2024 Mar; 51(3):441-447. PubMed ID: 38115742
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Treatments for Pruritus in Epidermolysis Bullosa.
Danial C; Adeduntan R; Gorell ES; Lucky AW; Paller AS; Bruckner AL; Pope E; Morel KD; Levy ML; Li S; Gilmore ES; Lane AT
Pediatr Dermatol; 2015; 32(5):628-34. PubMed ID: 25557557
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B; Trower M; Duggal A; Guglielmini P; Harris P; Jackson D; Lacouture ME; Ratti E; Tonini G; Wood A; Ständer S
BMJ Open; 2020 Feb; 10(2):e030114. PubMed ID: 32034016
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
18. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
Murata Y; Song M; Kikuchi H; Hisamichi K; Xu XL; Greenspan A; Kato M; Chiou CF; Kato T; Guzzo C; Thurmond RL; Ohtsuki M; Furue M
J Dermatol; 2015 Feb; 42(2):129-39. PubMed ID: 25491792
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial.
Welsh SE; Xiao C; Kaden AR; Brzezynski JL; Mohrman MA; Wang J; Smieszek SP; Przychodzen B; Ständer S; Polymeropoulos C; Birznieks G; Polymeropoulos MH
J Eur Acad Dermatol Venereol; 2021 May; 35(5):e338-e340. PubMed ID: 33330999
[No Abstract] [Full Text] [Related]
20. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
